Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DO7QK1
|
|||
| Drug Name |
KSI-301
|
|||
| Drug Type |
Antibody biopolymer conjugate
|
|||
| Indication | Diabetic macular edema [ICD-11: 9B71.02] | Phase 3 | [1] | |
| Company |
Kodiak Sciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor (VEGF) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04603937) A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) (GLIMMER). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Kodiak Sciences. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.